Seventeen patients at a bone clinic were not reaching adequate vitamin D blood levels despite taking supplements, usually on an empty stomach or with a light meal. They kept the same supplement and the same dose but took it with their largest meal instead. Blood levels rose by roughly half on average after 2 to 3 months, and the rise was similar across doses from 1,000 to 50,000 IU.
Doctors treating vitamin D deficiency often find blood levels stay low even on large prescribed doses. The authors, two Cleveland Clinic endocrinologists, noticed their patients usually took the supplement on an empty stomach or with a light breakfast. Vitamin D is fat soluble, meaning it dissolves in fat rather than water, so the food eaten alongside it may change how much is absorbed. They asked a narrow question: if the same patient takes the same dose with the biggest meal of the day, does the blood level rise?
A prospective cohort study approved by an institutional review board, run at a hospital bone clinic. Patients already treated for vitamin D deficiency, who had not achieved an adequate rise in blood levels, were told to keep the same supplement and dose but take it with their largest meal, usually supper. Blood 25-hydroxyvitamin D was measured again 2 to 3 months later using a chemiluminescence immunoassay, reference range 31 to 80 ng/mL, and compared with a paired t test. Seventeen patients were analyzed, mean age 64.5 plus or minus 11.0 years, 13 women and 4 men. Doses ranged from 1,000 to 50,000 IU daily. Many had conditions affecting absorption, including celiac disease, short bowel syndrome and liver transplant, alongside osteoporosis and hyperparathyroidism.
Mean blood 25-hydroxyvitamin D went from 30.5 plus or minus 4.7 ng/mL at baseline, range 21.6 to 38.8, to 47.2 plus or minus 10.9 ng/mL afterwards, range 34.7 to 74.0, P less than 0.01. The average rise was 56.7 percent plus or minus 36.7 percent. That spread is wide, so individual responses varied a lot.
The authors split the group by weekly dose:
The rise was around 50 percent in all three groups. The form of the supplement, oil-based or solid, did not appear to matter.
The authors list three limitations themselves: small sample size, no control group, and no way to know exactly how patients took their supplements. With 17 patients and no control arm, this is a before-and-after comparison in people picked because they had not responded to treatment, so movement back towards the average is an alternative explanation for the rise. The authors could not break down the fat, carbohydrate and protein content of meals, so they used meal size instead. The study does not report the season blood was drawn, and sunlight exposure was not controlled, though sunlight is a major source of vitamin D. Several patients had malabsorption conditions, unlike the general population. Both authors state they have no conflicts of interest, and no funding source is named. The article carries a standard publisher copyright line, copyright 2010 American Society for Bone and Mineral Research, with no Creative Commons statement.
This is a small, uncontrolled observation in a clinical group: bone clinic patients treated for deficiency, many with gut or liver conditions, average age 64. The result does not automatically extend to healthy or younger people, or to anyone whose levels are already normal. It suggests timing may affect absorption, but with no control group it cannot prove the meal caused the rise. It tests no health outcome, only a blood level, so it says nothing about fractures or muscle function.
That depends on the specific medication and formula. A few, like blood thinners with CurQLife or blood pressure medication with MaxiNOs, are worth a direct conversation with your doctor first. Check each formula's own FAQ section for specifics, or ask your health coach.
No, and we'd rather be upfront about it. Bacopa, the plant in BacoZest, has published human studies, though they used other bacopa extracts. OptiNOs and MaxiNOs each have human studies sponsored by their maker, Laila Nutraceuticals, which haven't been published in a journal. CurQLife's research is still early, from lab and animal studies, and we label it that way.
It depends on what you're building your routine around. BacoZest is built around bacopa, which is studied for memory.* OptiNOs supports strength and muscular endurance alongside resistance training.* MaxiNOs was studied for healthy blood vessel function.* CurQLife's research is still at the lab stage. Your health coach can help you pick a starting point.
All four are built around plant extracts. OptiNOs was reported as well tolerated in its human study, and published bacopa studies reported no serious side effects. CurQLife's safety data so far comes from lab and animal testing. Check with your doctor first if you're pregnant, nursing, on medication, or managing a health condition.
Because the patented ingredients behind our four formulas went through dedicated research, and research costs real money. A generic curcumin or bacopa supplement hasn't been tested in the form you get from us. You're paying for an ingredient with research behind it, not just a label.
Generic ingredients often haven't been studied in the specific form you're buying. Our four core formulas use patented ingredients, and we show you the research behind each one, including where it's still early.
It depends on the formula. In its study, MaxiNOs blood vessel response was higher than placebo 2 to 3 hours after the first dose.* OptiNOs and bacopa were studied over 6 and 12 weeks of daily use, so give them time. CurQLife is meant to be taken daily.
Yes. BacoZest, OptiNOs, MaxiNOs, and CurQLife are built for different goals, and none of them contain stimulants. They haven't been studied together, so ask your health coach how to fit them into your routine.
